NASDAQ$ITOS
iTeos Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
iTeos Therapeutics reported financial results for the third quarter ended September 30, 2020.
iTeos Therapeutics reported a net loss of $11.7 million for the third quarter of 2020, with a cash position of $340.0 million as of September 30, 2020. The company is focused on advancing its two lead candidates, EOS-850 and EOS-448, towards initial data readouts in the first half of 2021.
- Patient enrollment continues in Phase 1/2 studies of EOS-850 A2AR antagonist and EOS-448 FCgR-enabled anti-TIGIT antibody with initial data expected in 1H21.
- iTeos expects to nominate a new drug product candidate before the end of 2021.
- Completed Initial Public Offering (IPO) raising $229.7 million in gross proceeds.
- The Company’s cash and cash equivalent position was $340.0 million as of September 30, 2020.
Headline financials
Revenue & EPS history
iTeos Therapeutics · Revenue · Quarterly
$35M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
+0.8%
Avg return
Earnings day
+7.3%
Avg return
5 days after
+11.8%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+39.6%
Q1 2024
Best reaction
-11.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.2% | +0.0% | — | |
| Q1 2025 | -0.4% | +13.3% | +52.2% | |
| Q4 2024 | -3.7% | -6.4% | -11.4% | |
| Q3 2024 | -5.9% | -12.4% | -15.6% | |
| Q2 2024 | -3.4% | +1.4% | -3.1% | |
| Q1 2024 | +39.6% | +47.5% | +36.9% | |
| Q4 2023 | +5.1% | +8.0% | +12.0% | |
| Q3 2023 | -3.1% | — | — | |
| Q2 2023 | -2.6% | — | — | |
| Q1 2023 | -0.8% | — | — | |
| Q4 2022 | -7.7% | — | — | |
| Q3 2022 | +16.2% | — | — | |
| Q2 2022 | -9.4% | — | — | |
| Q1 2022 | +3.2% | — | — | |
| Q4 2021 | -3.6% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | -1.5% | — | — | |
| Q1 2021 | +8.5% | — | — | |
| Q4 2020 | -11.1% | — | — | |
| Q3 2020 | -4.2% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro